Patents Assigned to AstraZeneca
  • 4-anilino quinazoline derivatives as antiproliferative agents
    Patent number: 8399667
    Abstract: The invention concerns quinazoline derivatives of Formula (I) wherein each of Q1, Z, R1 and Q2 have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumours which are sensitive to inhibition of erbB receptor tyrosine kinases.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: March 19, 2013
    Assignee: Astrazeneca AB
    Inventors: Robert Hugh Bradbury, Laurent Francois Andre Hennequin, Jason Grant Kettle
  • Inhaler comprising a base having at least one sealed cavity containing medicament
    Patent number: 8397718
    Abstract: An inhaler which comprises a base having at least one sealed cavity containing medicament and a foil portion comprising two sides, one side being attached to the base for sealing the medicament within the cavity. A separating element is attached to the other side of the foil portion for separating the foil portion from the cavity, the separating element having a first end and an opposite second end, wherein the separating element is movable to an intermediate tilted position in which said first end is moved-away from the cavity. The separating element is further movable from the intermediate tilted position to a removed position in which also said second end is moved-away from the cavity so that the foil portion is removed from the cavity which is thereby uncovered so that medicament contained therein is enabled to become entrained in a fluid flow.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: March 19, 2013
    Assignee: AstraZeneca AB
    Inventor: Orest Lastow
  • Methods of treating obesity with two different anti-obesity agents
    Patent number: 8394765
    Abstract: Methods for treating obesity or obesity related disorders are disclosed. These methods include the use of anti-obesity agents directed to the forebrain in combination with anti-obesity agents directed to the hindbrain.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: March 12, 2013
    Assignees: Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Jonathan D. Roth, Christen M. Anderson, Alain D. Baron
  • Inhaler comprising a base having a plurality of medicament containing sealed cavities
    Patent number: 8393322
    Abstract: An inhaler which comprises a base having a plurality of consecutive sealed cavities containing medicament. Foil portions are on one side attached to the base for sealing the medicament within respective associated cavities. A plurality of separating elements are attached to the other side of the foil portions, each separating element being associated with a respective cavity for separating a foil portion from that cavity. Each separating element can be moved-away from its associated cavity so that the sealing foil portion is separated from the cavity which is thereby uncovered so that medicament contained therein is enabled to become entrained in a fluid flow, and then returned with the attached foil portion to cover its associated cavity. A method of operating an inhaler is also disclosed.
    Type: Grant
    Filed: February 11, 2009
    Date of Patent: March 12, 2013
    Assignee: AstraZeneca AB
    Inventor: Orest Lastow
  • Phenoxiacetic acid derivatives
    Patent number: 8394986
    Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
    Type: Grant
    Filed: July 26, 2011
    Date of Patent: March 12, 2013
    Assignee: AstraZeneca AB
    Inventors: Roger Victor Bonnert, Anil Patel, Stephen Thom
  • USE OF MYELOPEROXIDASE (MPO) INHIBITORS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF TO TREAT MULTIPLE SYSYEM ATROPHY (MSA) 938
    Publication number: 20130059870
    Abstract: The present invention relates to the use of MPO inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection.
    Type: Application
    Filed: November 1, 2012
    Publication date: March 7, 2013
    Applicant: AstraZeneca AB
    Inventor: AstraZeneca AB
  • Amylin and amylin agonists for treating psychiatric diseases and disorders
    Patent number: 8389477
    Abstract: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: March 5, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Kevin D. Laugero, Michael R. Hanley, Christine M. Mack, David G. Parkes, Andrew A. Young
  • Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
    Patent number: 8389472
    Abstract: The present invention relates generally to the novel use of incretin compounds (ICs) and amylinomimetic compounds to treat, prevent, or ameliorate a variety of metabolic conditions or diseases.
    Type: Grant
    Filed: August 21, 2006
    Date of Patent: March 5, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: Alain D. Baron, Dennis Kim, David G. Maggs, Matthew Wintle
  • Treatment of cardiac arrhythmias
    Patent number: 8389473
    Abstract: Compositions of the invention, including compounds that bind to a receptor for a glucagon-like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an agonist, an analog (preferably an agonist analog), a derivative, or a variant of any of aforementioned compounds, are used in the prevention and treatment of arrhythmias associated with cardiac ischemia, cardiac ischemia-perfusion and/or congestive heart failure. The invention relates to both the method and compositions for such treatment.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: March 5, 2013
    Assignees: Amylin Pharmaceuticals, LLC, AstraZeneca Pharmaceuticals LP
    Inventors: David R. Hathaway, Alain D. Baron
  • Crystalline forms
    Patent number: 8389510
    Abstract: 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine, compositions thereof, preparations thereof, formulations thereof, prodrugs thereof and pharmaceutical uses thereof.
    Type: Grant
    Filed: March 18, 2010
    Date of Patent: March 5, 2013
    Assignee: AstraZeneca AB
    Inventors: Simon N. Black, Simon D. Broady, Alan S. Kirschner, James A. Osborn, Stewart D. Jolly, Dan B. Brown, Daniel Korey, Karen B. Main, Richard J. R. Creekmore, Jean M. Surian, Vivian Y. Bi, Peter Bernstein, James B. Campbell, Greg Christoph, Scott W. Grimm, Dan Widzowski, James Hulsizer, Phil Edwards
  • Inhaler cap strap
    Patent number: 8387615
    Abstract: An inhaler (1) for dispensing doses of medicament from a container under user activation said inhaling which comprises a body (7) which includes a mouthpiece (5) through which the medicament is dispensed and a cap (2) which can be place in a position to substantially occlude the mouthpiece (5). The cap (2) is attached to said body (7) by a strap (3) which pivots from said body (7), said cap (2) being arranged to slide on the strap (3) such that the cap (2) must translate away from the mouthpiece (5) prior to the pivoting of the strap (3).
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: March 5, 2013
    Assignee: AstraZeneca AB
    Inventor: Martin Bunce
  • 2-(2,4,5-SUBSTITUTED-ANILINO) PYRIMIDINE COMPOUNDS
    Publication number: 20130053409
    Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
    Type: Application
    Filed: July 25, 2012
    Publication date: February 28, 2013
    Applicant: ASTRAZENECA AB
    Inventors: Sam BUTTERWORTH, Maurice Raymond Verschoyle FINLAY, Richard Andrew WARD, Vasantha Krishna KADAMBAR, Chandrashekar Reddy C MURUGAN, Andiappan MURUGAN, Heather Marie REDFEARN
  • Process for preparing benzimidazole compounds
    Patent number: 8383832
    Abstract: Provided are methods for the synthesis of heterocyclic compounds such as benzimidazole carboxylic acid core structures having Formula Ib-1: wherein Z, X1, X2, X5, R2b and R10 are as defined herein. Compounds of Formula Ib-1 can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: February 26, 2013
    Assignees: Array BioPharma Inc., AstraZeneca AB
    Inventors: John Demattei, Sagar Shakya, Anthony D. Piscopio, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, Simon Mark Pointon, Koen Peeters, Timothy John Lilley, John Leonard
  • Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842
    Patent number: 8377940
    Abstract: Compounds of Formula (I) wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: February 19, 2013
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842
    Patent number: 8377939
    Abstract: Compounds of Formula I: wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: February 19, 2013
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Co-Crystals Of A Triazolo [4,5-D] Pyrimide Platelet Aggregation Inhibitor
    Publication number: 20130040970
    Abstract: The present invention relates to novel co-crystal forms of the compound of formula (I); wherein the co-former molecule is selected from glycolic acid, salicylic acid, decanoic (capric) acid, gentisic acid (2,5-dihydroxybenzoic acid), glutaric acid, vanillic acid (4-hydroxy-3-methoxybenzoic acid), succinic acid, malonic acid or maltol (3-hydroxy-2-methyl-4-pyrone); and to processes for their preparation, to pharmaceutical compositions containing such co-crystals, to the use of such co-crystals in the manufacture of a medicament for use in the prevention of arterial thrombotic complications in patients with coronary artery, cerebrovascular or peripheral vascular disease and to methods of treating such diseases in the human or animal body by administering a therapeutically effective amount of a co-crystal of the compound of formula (I).
    Type: Application
    Filed: December 3, 2010
    Publication date: February 14, 2013
    Applicant: AstraZeneca AB
    Inventors: Stephen David Cosgrove, Matthew Jonathan Jones, Anna Polyakova-Akkus, Valeriya Nikolayevna Smolenskaya, Brenton Skylar Wolfe
  • Package
    Patent number: 8371449
    Abstract: A package for a dispensing device, comprising a protection pouch arranged to enclose the dispensing device. The protection pouch comprises a base section that is arranged to support the dispensing device in the general vertical direction, and the package comprises a support member arranged to essentially elevate the base section of the pouch from a support surface.
    Type: Grant
    Filed: July 27, 2011
    Date of Patent: February 12, 2013
    Assignee: AstraZeneca
    Inventors: Simon Berry, Eric Connolly, Dave Salmon
  • AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS
    Publication number: 20130035346
    Abstract: The invention concerns a compound of the Formula (I), wherein Qa is heteroaryl and is substituted with halogeno; R1 and R2 are hydrogen; and Qb is phenyl or heteroaryl, and Qb may optionally bear 1 or 2 substituents selected from hydroxy, halogeno and (1-6C)alkyl, or a pharmaceutically-acceptable salt thereof; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines.
    Type: Application
    Filed: September 27, 2012
    Publication date: February 7, 2013
    Applicant: AstraZeneca AB
    Inventor: AstraZeneca AB
  • IMMEDIATE RELEASE TABLET FORMULATIONS
    Publication number: 20130034606
    Abstract: The present invention provides an immediate release pharmaceutical formulation which includes a tablet or capsule formulation comprising metformin and the sodium dependent glucose transporter (SGLT2) inhibitor dapagliflozin or its propylene glycol hydrate. The present invention also provides methods of preparing the formulations and methods of treating diseases or disorders associated with SGLT2 activity employing these formulations.
    Type: Application
    Filed: November 12, 2010
    Publication date: February 7, 2013
    Applicants: ASTRAZENECA UK LIMITED, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Agneta Hallgren, Ralf Magnus Werner Swenson
  • 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
    Patent number: 8367676
    Abstract: The present invention relates to compounds of formula (I), wherein R1 is heteroaryl or heterocyclyl, optionally substituted; R2 is C1-4alkyl, heterocyclyl, C1-4alkylaryl, C1-4alkylheteroaryl, carbocyclyl, C1-4alkylheterocyclyl, heterocyclyl-heteroaryl, aryl-heterocyclyl, carbocyclyl-heteroaryl, heterocyclyl-aryl, optionally substituted; R3 is hydrogen or C1-4alkyl, or R2 and R3 may together with the nitrogen atom, form a saturated ring system containing 4, 5 or 6 ring forming atoms, and optionally substituted; R4 is hydrogen, halogen, methyl or methoxy; to pharmaceutical composition containing said compounds and to the use of said compounds in therapy, for instance in treating cognitive disorders. The present invention further relates to new intermediates useful in the preparation thereof.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: February 5, 2013
    Assignee: AstraZeneca AB
    Inventors: Johan Andersson, Helena Gybäck, Anh Johansson, Christian Erik Linde, Jonas Malmström, Gunnar Nordvall, Tatjana Weigelt, Gitte Terp